88 Pharmacist-driven pain management service for patients at high risk for respiratory depression

Wednesday, May 18, 2016
Dr. Olga Zirka, Pharm.D.
Department of Pharmacy, Southwest General Health Center, Middleburg Heights, OH 44130, OH
Service or Program: Pharmacist-driven pain management service for patients at high risk for respiratory depression Justification/Documentation: Millions of Americans are affected by pain on a daily basis, and significant disparities exist in appropriate pain management – both in the inpatient and outpatient setting. Furthermore, opioid analgesics rank among the drugs most frequently associated with adverse drug events. In recognition of the nationwide epidemic of opioid-induced respiratory depression and over-sedation, The Joint Commission released Sentinel Event Alert #49 on the safe use of opioids that are prescribed and administered within the inpatient hospital setting. The Alert provides a number of evidence-based recommendations that can be taken to avoid the unintended consequences of opioid use among hospital inpatients, one of which is to create and implement policies and procedures for a second-level review of pain management plans with high-risk opioids by pain specialists or pharmacists. The primary objective of this service is to evaluate the effect of an inpatient pharmacist-driven pain management service and opioid stewardship on the number of respiratory depression and over-sedation cases, amount and types of opioids prescribed, patient pain scores and overall patient outcomes and satisfaction. Transferability: A pharmacist-driven service that offers the second-level review of pain management plans is a service that can be carried out in a variety of different care settings, particularly in the hospital acute-care setting. Impact: A pharmacist-driven pain management service offered to inpatients at high risk for respiratory depression can make a great impact on patient safety and satisfaction. Second-level review and optimization of pain medication regimens can reduce the incidence of opioid-related adverse effects such as over-sedation and respiratory depression, and improve patient outcomes and satisfaction.